Clinical trials: GLUT-1 Deficiency Syndrome
Glucose Transporter Type 1 Deficiency Syndrome, GLUT1 Deficiency Syndrome
Treatment Development for Glucose Transporter Type I Deficiency Syndrome (G1D)
The purpose of this trial is to determine if an alternative energy source will impact brain metabolism in a disorder characterized by glucose metabolism failure in the brain.
- Trial name
- NCT02018315
- Testing
- Triheptanoin
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Juan Pascual
Glucose Transporter Type 1 Deficiency Syndrome, GLUT1DS1
Red Blood Cell Exchange Transfusion as a Novel Treatment for GLUT1 Deficiency Syndrome
Pathogenic mutations of the brain glucose transporter type I lead to glucose transporter deficiency syndrome (G1D), which is most often associated with medication-refractory epilepsy and movement dysfunction.
- Trial name
- NCT04137692
- Testing
- Red Blood Cell Transfusion
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Weill Medical College of Cornell University
GLUT1DS1, Epilepsy
Diet Treatment Glucose Transporter Type 1 Deficiency (G1D)
Forty-five subjects receiving no dietary therapy with a proven G1D diagnosis will be enrolled. To evaluate the effect of C7 supplementation of a regular diet on a EEG activity in addition to IQ, language, working memory…
- Conditions
- GLUT1DS1, Epilepsy, Glut1 Deficiency Syndrome 1, Autosomal Recessive, Glucose Metabolism Disorders
- Trial name
- NCT03181399
- Testing
- Triheptanoin
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Texas Southwestern Medical Center